The Peptide Era Has Arrived

EDITORIALS OCTOBER 2026

Dr. David A. Sinclair, A.O., Ph.D.

16 minute read

If you follow longevity closely, and even if you don’t, you have probably heard about peptides. Once the purview of researchers and doctors, peptides are now discussed in gyms, on podcasts and across social media. Longevity clinics offer them for recovery, fat loss, muscle growth, sleep, cognition, skin health and, increasingly, aging itself. Some people are ordering vials online marked “For Research Use Only.” ¹^,²

With so many peptides now available, how do we distinguish those that are safe and effective from those whose claims have outpaced the science?

Some of this reflects serious science. Some of it is an uncontrolled experiment whose scale is difficult to measure. As a scientist who studies aging, I find that combination of promise and uncertainty one of the most interesting developments in health and longevity.

Peptides themselves are nothing new. In fact, they are as old as life itself: short chains of amino acids our bodies use to send signals within and between cells. Insulin, GLP-1 receptor agonists (GLP-1RA) and oxytocin are peptides. Some of the most successful medicines ever developed belong to this broad class.

The extraordinary success of GLP-1RA drugs has reminded the public and the pharmaceutical industry just how powerful peptide biology can be. We now have peptide-based medicines that can produce profound changes in metabolism and body weight, and the next generation is already coming. Retatrutide, which activates GIP, GLP-1 and glucagon receptors, produced an average weight loss of 28.3% at the highest dose after 80 weeks in the Phase 3 TRIUMPH-1 obesity trial, according to results reported by Eli Lilly.³

In the last few years, peptides have moved beyond pharmaceutical research to biohacking circles and now into pop-culture. Names such as BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu, MOTS-c, KPV, Epitalon and Semax are increasingly familiar to longevity enthusiasts, weight trainers and the wider public. They are often lumped together under the heading of “peptide therapy,” which makes very little scientific sense because their biological effects and the evidence behind them vary enormously. With so many peptides now available, how do we distinguish those that are safe and effective from those whose claims have outpaced the science?

First, there are insulins and GLP-1 drugs, which have proven benefits, with improved versions continuing to emerge. Products sold under the name retatrutide, which is still undergoing clinical trials, have already found their way into the grey market. The grey market refers to products sold through unauthorized or unofficial distribution channels, often beyond the practical reach of regulatory oversight. In the case of retatrutide, even promising Phase 3 trial results do not tell us what is in a vial bought online, or whether its purity and dose match the drug being studied.³^,⁴

Some lesser-known peptide drugs do have human evidence, but for specific uses. Tesamorelin, for example, is approved by the FDA to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. That does not make it a general longevity treatment or a weight-loss drug for everyone. It means that, in a defined population and for a defined indication, there is demonstrated benefit. Reported adverse reactions include joint pain, injection-site reactions and swelling from fluid retention. Approved does not mean risk-free or that it works “off-label”. ⁵

Another fascinating example is SS-31, or elamipretide, now sold as Forzinity. The mitochondria-targeted peptide — not to be confused with a mitochondrial-derived peptide like humanin and MOTS-c — interacts with the inner mitochondrial membrane and has been studied for years in disorders of mitochondrial function. The FDA granted accelerated approval in 2025 to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kilograms. Approval was based on knee-extensor strength, an intermediate clinical endpoint; a confirmatory trial is required to verify clinical benefit.⁶ It is not approved for use by healthy people.

Then there is a second group of peptides that clearly do something in humans, but where the claims have run well ahead of what has been demonstrated. CJC-1295 is a long-acting analogue of growth hormone releasing hormone, and controlled human studies show that it increases growth hormone and IGF-1. Ipamorelin also stimulates growth hormone release, through the ghrelin receptor. Those are genuine physiological effects, and we know that increasing growth hormone may alter body composition. But whether these changes improve long-term health is a separate question.⁷^,⁸

Reduced growth hormone signaling can extend lifespan in mice. In an Ecuadorian population with inherited growth hormone receptor deficiency, researchers also found unusually low rates of cancer and diabetes. That does not establish that lowering growth hormone in healthy adults would extend their lives, but it challenges the assumption that increasing it must be rejuvenating. Biology tends to involve trade-offs and many things can make you feel better without making you biologically younger or protected from diseases later in life. ⁹^,¹⁰

There are also safety concerns. In a randomized trial of growth hormone in healthy older adults, adverse effects included fluid retention, joint symptoms and glucose intolerance or diabetes. That was a study of growth hormone itself, so it cannot tell us the precise risks of CJC-1295 or ipamorelin, but it shows why stimulating this hormonal system deserves caution. Short studies of CJC-1295 and intravenous ipamorelin do not establish the long-term safety of the combinations now marketed for recovery and longevity. ⁷^,¹¹^,¹²

Then we get to the peptides generating perhaps the most excitement despite having little convincing human evidence. BPC-157, short for Body Protection Compound-157, is a synthetic 15-amino-acid peptide promoted for tendon, ligament, muscle and gut repair. Combined with TB-500, it is sometimes called the “Wolverine stack”, an informal term rather than a medical designation. ¹³ Reuters reported a 33-fold increase in newly documented users between 2020 and 2026¹³ and published human reports include a series on uncontrolled knee pain and an intravenous safety pilot involving just two people.¹³^,¹⁴^,¹⁵ That does not mean BPC-157 is dangerous but it is something to talk to your doctor about if you choose to try peptides.

TB-500 is even more confusing because the name itself can hide an important distinction. It is related to thymosin beta-4, a naturally occurring peptide involved in actin regulation, cell migration and tissue repair. An analytical study identified a short, seven-amino-acid fragment of thymosin beta-4 in a product sold as TB-500. Full-length thymosin beta-4 has undergone human clinical research, but that evidence cannot simply be transferred to the fragment or to whatever is being sold online as TB-500. ¹⁶^,¹⁷

Peptides: Human Evidence, Uses and Regulatory Status

Peptide	What people tend to use it for	Human Evidence and U.S. Regulatory status	Safety / uncertainties
BPC-157	Tendon, muscle, ligament and gut repair	Tiny uncontrolled human reports; no convincing randomized evidence of healing benefit. IV safety pilot: two people. FDA: Not approved.	Human safety poorly defined. Immune reactions and impurities are concerns. Cancer promotion is theoretical, not demonstrated.
TB-500	Injury recovery and wound repair	No established benefit for commercial TB-500. Evidence for full-length thymosin beta-4 cannot automatically be assumed to apply. FDA: Not approved.	Sparse human data; variable product identity; immune and impurity concerns.
CJC-1295	GH release, muscle, sleep and fat loss	Raises GH and IGF-1 in humans, but longevity and recovery benefits are unproven. FDA: Not approved.	Flushing, headache, injection reactions; reported tachycardia and vasodilatory reactions. Longevity trade-offs unresolved.
Ipamorelin	GH release, sleep and recovery	Human GH-secretagogue activity is established, but no anti-aging benefit has been demonstrated. FDA: Not approved.	Long-term safety unclear; possible GH-related edema and glucose effects.
Tesamorelin	Reduction of visceral abdominal fat	Randomized evidence in HIV-associated lipodystrophy; not general weight loss or longevity. FDA: Approved for HIV-associated lipodystrophy.	Elevated IGF-1, edema, joint pain, glucose intolerance and hypersensitivity. Active malignancy is a contraindication.
GHK-Cu	Skin, wound repair and hair claims	Limited evidence for topical skin benefit; injectable rejuvenation and reliable hair regrowth are unproven. FDA: No approved drug; non-injectable GHK-Cu has Category 1 interim status.	Topical irritation; injectable safety and immunogenicity inadequately defined.
MOTS-c	Metabolic resilience, endurance and healthy-aging claims	Human studies measure endogenous MOTS-c and exercise responses; injected efficacy remains largely preclinical. FDA: Not approved.	Insufficient treatment data to establish common adverse effects or long-term safety.
Epitalon / Epithalon	Telomeres, sleep and longevity	Telomere effects reported in cell-culture studies; no convincing evidence of human lifespan extension. FDA: Not approved.	Long-term safety uncertain; consequences of telomerase modulation remain unclear.
Cerebrolysin	Stroke/TBI recovery and dementia	Mixed disease-specific clinical trials; no proven healthy-brain rejuvenation. FDA: Not approved in the U.S.	Hypersensitivity and infusion reactions; some stroke studies raised concern about nonfatal serious adverse events.
Semax	Focus, memory and neuroprotection	Limited clinical literature, mainly from Russia and neighboring regions; no persuasive healthy-adult anti-aging evidence. FDA: Not approved in the U.S.	Long-term safety poorly characterized; nasal tolerability and immune effects remain uncertain.
SS-31 / Elamipretide	Mitochondrial dysfunction	Accelerated approval based on knee-extensor strength in Barth syndrome; confirmatory benefit still required. FDA: Approved in 2025 for Barth syndrome, weight ≥30 kg.	Frequent injection-site redness, pain and itching; hypersensitivity. Approval is for a rare-disease indication, not longevity.

Notes: FDA approval applies to a specific product and indication. A compounded preparation is not itself FDA approved. Evidence of a biomarker effect is not evidence of improved healthspan or lifespan. This table is an educational research summary, not a dosing or treatment guide.

GHK-Cu, a copper-binding tripeptide, is used in cosmetic products for skin aging.¹⁸ Its topical human evidence is limited and not uniformly positive: in one small, randomized study after laser resurfacing, users reported greater satisfaction, but investigators found no significant additional improvement in wrinkles, redness or overall skin quality. Claims that injectable GHK-Cu rejuvenates the body or reliably regrows hair are much further ahead of the data.¹⁸^,¹⁹

Epitalon sits in another part of the peptide landscape. It is often promoted for telomeres, sleep and longevity, partly because of experiments suggesting effects on telomerase and telomere biology in cultured cells. But there is no convincing evidence that injecting Epitalon lengthens telomeres throughout a person’s body or extends human life. It is also important to distinguish synthetic Epitalon from Epithalamin, an animal pineal-gland extract used in some of the human studies cited to support it.²⁰^,²¹

Telomerase also deserves caution: cancer cells can exploit it to keep dividing. A 2025 cell-culture study found that Epitalon lengthened telomeres in cells via telomerase activation, and in breast cancer cell lines through a different telomere-maintenance mechanism. This does not mean Epitalon causes cancer in humans, but it raises a safety question that short experiments cannot answer.²⁰

Semax has a longer clinical history that predates today’s peptide boom.²² Developed by scientists led by Igor Ashmarin and Nikolai Myasoedov at Moscow’s Institute of Molecular Genetics, it is a synthetic seven-amino-acid peptide based on a fragment of ACTH, a hormone involved in the body’s stress response. In 1997, Russian researchers compared 30 stroke patients given Semax with 80 patients receiving conventional treatment alone. They reported faster recovery of some neurological functions, including movement, although the study was small and its abstract did not describe randomization or blinding.

That history gives Semax more clinical validity than many peptides now sold online, but a treatment investigated after brain injury is not automatically a proven treatment for keeping a healthy brain young. Today, in Russia and elsewhere, Semax is promoted for cognitive enhancement, but evidence that it improves cognition or slows brain aging in healthy people remains limited.²³

Cerebrolysin, an Austrian-made mixture of peptides and amino acids made from pig brains, presents a similar lesson. It has been used in neurological medicine in Russia, Eastern Europe, China and other Asian and post-Soviet countries.²⁴ There are human trials in stroke and brain injury, but the results are mixed and disease-specific. A Cochrane review of acute ischemic stroke found no convincing decrease in mortality and a probable increase in serious nonfatal adverse events.²⁴

KPV is a three-amino-acid fragment derived from α-melanocyte-stimulating hormone (α-MSH) and is studied mainly for anti-inflammatory effects, especially in the gut and skin. KPV reduces inflammation in mouse models of colitis²⁵ but reliable patient-use figures are not yet available, and the broad claims are way ahead of the human evidence.²³

And then there is MOTS-c, which is especially interesting to me because I have had the pleasure of collaborating with scientists whose work helped establish much of the biology of mitochondrial-derived peptides, Professor Pinchas “Hassy” Cohen and Dr. Changhan David Lee. ²⁶ Mitochondria are descended from ancient bacteria that entered a symbiotic relationship with our ancestors more than a billion years ago, and they retain a tiny circular genome of their own. What makes mitochondrial-derived peptides so intriguing is that some of them are encoded by small regions within that mitochondrial genome. In other words, mitochondria are not merely taking orders from the nucleus. They can generate peptide signals of their own.²⁶^,²⁷

Humanin was the first mitochondrial-derived peptide to be identified, in 2001. MOTS-c followed in 2015.²⁶^,²⁷ Dr. Cohen and his colleagues have helped expand this family, giving members names such as SHLPs, small humanin-like peptides pronounced “schleps,” SHMOOSE and MENTSH, a playful nod to his Jewish heritage.²⁸

MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA and appears to participate in metabolic regulation and stress responses. In experimental systems it affects folate and purine metabolism, activates AMPK, and under stress can participate in signaling between mitochondria and the nucleus. This suggests that the two genomes inside our cells are engaged in a conversation.²⁶^,²⁹ Mitochondrial dysfunction and loss of metabolic resilience are deeply connected with aging. A system in which mitochondria communicate their condition to the rest of the cell could therefore be important in how organisms respond to stress and maintain function over time.²⁶^,²⁹

But once again, fascinating biology is not the same as a therapy. Endogenous MOTS-c has been studied in humans in relation to exercise and metabolism, while treatment experiments have shown effects on physical performance in mice. ³⁰ Evidence that injecting synthetic MOTS-c makes people healthier or extends healthspan remains insufficient and the published exercise research does not establish the safety or effectiveness of the synthetic injections now being sold.¹^,³⁰

My own laboratory is looking for peptides in “junk” DNA. There is a world of small proteins and peptides encoded in regions of our genomes that for years were either poorly annotated or assumed not to make anything important. This is sometimes referred to as the dark proteome. Many of these molecules are difficult to detect because they are small, short-lived or produced only under specific conditions.³¹

In my lab we have developed a program called GeneFinder to search for these hidden coding regions. In unpublished work using it, we have identified hundreds of possible peptides in human serum that we are now studying for rejuvenative properties. The obvious questions are what tissues make them, what receptors they interact with and what they do? These are the kinds of questions that help turn an interesting molecule into a potential medicine. Yet, for many peptides already being sold, their use is moving ahead of basic knowledge about their benefits and risks.

That tension reached the FDA in 2026, when its Pharmacy Compounding Advisory Committee considered BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon and emideltide for possible inclusion on the 503A Bulks List, which governs certain ingredients used by compounding pharmacies. The committee provides expert advice, but its recommendations are not legally binding, and inclusion on the list would not amount to FDA approval of a peptide’s safety or effectiveness.

The debate has also taken an unusually political turn. US Health Secretary Robert F. Kennedy Jr. has supported broader access to peptides and said he has used them himself. Reuters reported in 2026 that he backed BPC-157 compounding and that advisers had voted in favor, while the FDA’s decision remained pending. Whatever the outcome, broader access will leave the scientific questions facing my lab and others much the same: what do these molecules do, who might benefit, and at what risk?

The deeper question is more interesting. How much evidence should an informed adult need before being allowed access to an experimental treatment? One view is that people should not have to wait a decade while a conventional drug-development process runs its course, particularly if they are extremely sick and a molecule has compelling biology and an apparently acceptable safety profile. The other view is that the history of medicine is full of plausible treatments that eventually failed, or harmed people, when they were finally tested properly. Both points deserve to be taken seriously.

There is an important distinction between an FDA-approved drug, a compounded preparation and a grey-market product. An FDA-approved drug has gone through review as a specific manufactured product for a specific indication. A compounded drug may be prepared legally under circumstances, but the finished product is not FDA approved. And a peptide sold online with “research use only” written on the label has not suddenly become authorized for self-injection because of those words.³²

This may sound like a boring regulatory detail, but it matters because consumers see phrases such as “doctor prescribed,” “compounded,” “pharmaceutical grade” or “research grade” and understandably assume that someone has established that the substance is safe and effective. Sometimes, no one has.

And with injectable molecules, quality matters enormously. Is what is written on the vial inside it? Is the concentration correct? Is it sterile? Has the peptide degraded? Are there synthesis by-products? Is there endotoxin present? What happens when several peptides are combined into a “stack” when interaction data are essentially nonexistent?¹^,⁴

Across these products, the risks include both the molecule and the vial. Unauthorized injections may contain the wrong amount of peptide, unwanted ingredients or microbial contamination, creating risks of infection and serious reactions. Peptide impurities and aggregation can also provoke unwanted immune responses. For BPC-157, TB-500, injectable GHK-Cu, Semax, KPV and MOTS-c, human safety evidence remains too limited to define the risks confidently, especially with repeated use. Combining several into a “stack” adds uncertainty about interactions and makes it harder to identify what caused a problem.¹^,⁴^,²³

[In India], a planned “peptide party” reportedly attracted more than 200 registrations before authorities cancelled it

The geography of the peptide boom is fascinating too. The peptide boom is now clearly visible in America's wealthiest cities. In Los Angeles, peptides have become part of the weight loss, recovery, beauty and longevity culture, offered alongside glutathione and NAD⁺ drips, from Beverly Hills to West Hollywood. One LA clinic directory now describes peptides as having gone from a “biohacker secret” to one of the city's mainstream wellness offerings in roughly two years. In New York, they are increasingly appearing in concierge medicine, men's health and high-end aesthetics, even becoming part of the latest pursuit of lean, muscular “trophy arms.”

A US phenomenon just a year ago, a grey market of peptides has now gone global. In India, peptides are now being sold online and offered through wellness and longevity clinics. In Bengaluru, a planned “peptide party” reportedly attracted more than 200 registrations before authorities cancelled it ³³ In Australia, a product sold as retatrutide was found to contain semaglutide and was linked to severe vomiting and a torn esophagus.⁴

And peptides may only be the beginning. There is an obvious next step. If a peptide might be beneficial, why inject it repeatedly? Why not give the body instructions to make it? That takes us from peptide therapy into gene therapy.

Follistatin is a particularly interesting example of where this longevity trend might soon be heading. Minicircle is one of the companies attempting to move these ideas into people. It uses a nonviral, plasmid-based approach intended to cause the body to produce proteins such as follistatin for an extended period to increase muscle growth. Popular Mechanics reported on its experimental treatment in Roatán, Honduras, where Bryan Johnson received injections at an offshore clinic. That illustrates the international access model but does not establish that the intervention slows aging or is safe over the long term.³⁷

Minicircle is also among the 20 finalist teams announced in 2026 for the $101 million XPRIZE Healthspan competition. Finalists will conduct clinical trials designed to measure effects on muscle, cognition and immune function in people between 50 and 80 years old. Selection is not an endorsement that a therapy is proven; it creates an opportunity to test whether the approach delivers meaningful benefits.³⁸

There is something valuable about allowing genuinely innovative ideas to reach human testing without requiring billions of dollars and a decade of conventional pharmaceutical development. At the same time, the stakes rise considerably when you move from injecting a peptide that disappears relatively quickly to delivering genetic instructions that may cause your cells to produce a protein for an extended period of time. Stopping further treatment would not necessarily stop protein production already underway.³⁹

More muscle sounds desirable in an older person. But myostatin and activin signaling exist for reasons. Follistatin interacts with a biological network, not a single switch marked “muscle.” The same is true of Klotho. A protein associated with longevity in mice may still have an optimal dose, tissue distribution and duration in humans, and chronic elevation could have consequences we have not anticipated.³⁴^,³⁵^,³⁶

Despite the warnings, there is also something about this movement that I find encouraging. An increasing number of people want to understand and improve their own biology. They want to know how tissues repair themselves, how mitochondria communicate, why inflammation increases with age and whether some of the decline we have accepted as inevitable can be changed.

Twenty years ago, many of these conversations would have stayed inside laboratories and medical conferences. Today they are happening in gyms, at dinner tables and on YouTube, albeit under “experimental” conditions that don’t tell us if they work or not. As a scientist, I think that curiosity is a good thing. But curiosity should make us more demanding of clinical evidence before we inject something, not less.

Some of today's popular peptides will probably fail. Some may turn out to be useful for narrow indications but have little to do with aging. Some may have risks that have not yet become apparent. A few may become important medicines.

That is why I think the peptide revolution is probably only beginning. The biology is moving very quickly. The challenge now is to make sure the experiments catch up.

References

1. Reuters. FDA panel to review popular peptides amid persistent consumer appetite. 2026. Source

2. The Guardian. “It’s a peptide wild west”: how RFK Jr is clearing way for a market of untested drugs. 2026. Reporting on Kennedy’s statements and advisory-panel recommendations. Source

3. Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. 2026. Sponsor announcement; TRIUMPH-1 results. Source

4. The Guardian. Peptide user tore oesophagus after using counterfeit product, Australian regulator warns. 2026. Source

5. U.S. Food and Drug Administration. EGRIFTA WR (tesamorelin) prescribing information. 2025. Source

6. U.S. Food and Drug Administration. FDA Grants Accelerated Approval to First Treatment for Barth Syndrome. 2025. Source

7. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006;91:799–805. Source

8. Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999;16:1412–1416. Source

9. Spadaro O, et al. Growth hormone receptor deficiency protects against age-related NLRP3 inflammasome activation and immune senescence. Cell Reports. 2016;14:1571–1580. Source

10. Guevara-Aguirre J, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Science Translational Medicine. 2011;3:70ra13. Source

11. Blackman MR, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA. 2002;288:2282–2292. Source

12. Beck DE, Sweeney WB, McCarter MD. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2014;29:1527–1534. Source

13. Reuters. Use of untested “Wolverine” peptide backed by US Health Secretary Kennedy on the rise, study finds. 2026. Reports an electronic-health-record analysis released before peer review. Source

14. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Alternative Therapies in Health and Medicine. 2021. Source

15. Lee E, Burgess D. Safety of intravenous infusion of BPC157 in humans: a pilot study. Alternative Therapies in Health and Medicine. 2025. Source

16. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis. 2012;4:733–738. Source

17. Ying Y, et al. Thymosin β4 and actin: binding modes, biological functions and clinical applications. Current Protein & Peptide Science. 2023;24:78–88. Source

18. Dou Y, et al. The potential of GHK as an anti-aging peptide. Aging Pathobiology and Therapeutics. 2020. Source

19. Miller TR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery. 2006;8:252–259. Source

20. Al-dulaimi S, et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26:178. Source

21. Araj SK, et al. Overview of Epitalon—highly bioactive pineal tetrapeptide with promising properties. International Journal of Molecular Sciences. 2025. Source

22. Deigin VI, et al. Development of peptide biopharmaceuticals in Russia. Pharmaceutics. 2022;14:716. Source

23. Health. FDA panel votes to ease restrictions on 6 peptides—but experts still have major concerns. 2026. Source

24. Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews. 2023;CD007026. Source

25. Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14:324–331. Source

26. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21:443–454. Source

27. Hashimoto Y, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Aβ. Proceedings of the National Academy of Sciences USA. 2001;98:6336–6341. Source

28. Elia-Shalev A. Many peptides are named to sound like Yiddish words. Here’s why. Jewish Telegraphic Agency, published by The Times of Israel. 2026. Source

29. Kim KH, et al. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism. 2018. Source

30. Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021. Source

31. Slavoff SA, et al. Peptidomic discovery of short open reading frame–encoded peptides in human cells. Nature Chemical Biology. 2013;9:59–64. Source

32. U.S. Food and Drug Administration. July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. 2026. Source

33. India Today. Bengaluru peptide party cancellation exposes India’s risky DIY wellness trend. 2026. Source

34. Mendell JR, et al. A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. Molecular Therapy. 2015;23:192–201. Source

35. Kurosu H, et al. Suppression of aging in mice by the hormone Klotho. Science. 2005;309:1829–1833. Source

36. Castner SA, et al. Longevity factor klotho enhances cognition in aged nonhuman primates. Nature Aging. 2023;3:931–937. Source

37. Popular Mechanics. Inside the secret tech island where death is optional. 2025. Source

38. XPRIZE Foundation. 20 Healthspan Finalist Teams Advance in the Race to Extend Healthy Aging. 2026. Source

39. Chen ZY, et al. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Molecular Therapy. 2003;8:495–500. Source

Lifespan Magazine is proud to support medical research and the Lifespan Foundation

Last Updated: Oct 8, 2026 · 16 minute read

Dr. David A. Sinclair, A.O., Ph.D.

Dr. David A. Sinclair, A.O., Ph.D. is Founder of Lifespan, Professor of Genetics at Harvard Medical School, and Co-Founder & Co-Chief Editor of the scientific journal Aging. Dr. Sinclair is considered one of the world’s most influential scientists and a leading figure in the study of human longevity. His pioneering work in genetics and aging biology has fundamentally shaped the world’s understanding of mechanisms of aging and age-related diseases. He has published 202 peer-reviewed scientific articles that have been cited over 110,000 times and is the inventor on more than 50 patents. Dr. Sinclair is the New York Times bestselling author of Lifespan: Why We Age-And Why We Don’t Have To, with over 1 million copies in global circulation across 38 languages, and is the host of Lifespan with Dr. David Sinclair, a #1 show on Apple which provides health and science education.